Vislyfa (ranibizumab)

Where it stands

Vislyfa (ranibizumab) is authorised in the EU. The European Commission decision of 15 July 2026 granted the marketing authorisation to Lupin Europe GmbH. The CHMP positive opinion came earlier, on 21 May 2026. The gap between the two is about eight weeks, which is consistent with the usual period for the Commission to convert a CHMP opinion into a legally binding decision.

The authorised indications are for adults: neovascular (wet) age-related macular degeneration; visual impairment due to diabetic macular oedema; proliferative diabetic retinopathy; visual impairment due to macular oedema secondary to retinal vein occlusion (branch or central); and visual impairment due to choroidal neovascularisation.

The records do not give a launch date, presentations, pricing or reimbursement status. Authorisation does not by itself tell us when the product will be commercially available in any member state.

Regulatory pathway and designations

Vislyfa carries a Biosimilar designation. In the EU this means it was assessed through the biosimilar pathway, in which a product is evaluated against an already authorised reference biological medicine. The approval rests on a demonstration of similarity rather than a full standalone development programme. The records do not name the reference product, and they do not describe the comparability data package, so neither is discussed here.

The record shows a conventional EU centralised sequence: CHMP positive opinion, then an EC decision. No other designations, such as orphan or conditional approval, are listed.

Ranibizumab is already a crowded EU space. The records list the same substance as Lucentis, Byooviz, Ximluci, Susvimo and Epruvy (previously Ranibizumab Midas), all Authorised. Fovlussea is listed at Opinion stage. Vislyfa is therefore entering a market with several authorised ranibizumab products and at least one more pending a Commission decision. The records give no detail on how those products differ, including their indications or presentations.

Safety and pharmacovigilance

The records contain no safety data, such as adverse-reaction profiles, immunogenicity findings or risk management plan content. This analysis therefore cannot characterise the product's safety profile.

The one pharmacovigilance-relevant fact in the record is the Additional monitoring designation. Products with this status are listed with a black inverted triangle in the product information, and healthcare professionals and patients are encouraged to report suspected adverse reactions. The status is a general transparency and data-collection measure. It does not, on its own, imply a specific safety concern with this product. It is commonly applied to biological medicines authorised relatively recently.

What to watch

The first item is the outcome for Fovlussea, which the records show at Opinion stage. An EC decision there would add another ranibizumab option in the EU. The records give no date for it.

The second is the commercial roll-out of Vislyfa. The records do not cover national launches, pricing, reimbursement or tender activity, so these would need to be tracked from other sources.

The third is the review of Additional monitoring status. It is normally reassessed over time, and early post-authorisation safety reporting for Vislyfa and the other ranibizumab products is worth following. The records do not indicate when any review might occur.